A Phase I/II Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas Aeruginosa.
Phase of Trial: Phase I/II
Latest Information Update: 07 Aug 2017
At a glance
- Drugs KB 001 (Primary)
- Indications Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
- Focus Adverse reactions
- Sponsors Humanigen
- 07 Aug 2017 According to Humanigen media release, KaloBios Pharmaceuticals changed its name to Humanigen.
- 18 May 2010 Results reported at American Thoracic Society meeting according to a KaloBios media release.
- 16 Oct 2009 Results have been reported at the North American Cystic Fibrosis Conference, according to a KaloBios Pharmaceuticals media release.